|
| |
 |
|
|
Supplement 5 to Volume 75, July 2008 |
Supplement Editor |
Brian F. Mandell, MD, PhD
Cleveland Clinic
|
Contents |
This supplement is based on the proceedings of a symposium, “The Hyperuricemia and Gout Summit,” held October 5, 2007, in Scottsdale, Ariz. All faculty presentations at the symposium were developed by the presenting physicians themselves. The symposium was organized logistically by Fallon Medica LLC, a medical communication company. Fallon Medica transcribed audio recordings of the symposium presentations and forwarded the transcripts to the respective physician presenters, who developed the transcripts into the articles published here without assistance from undeclared contributors. All but one of the articles underwent formatting and nonsubstantive copyediting by Fallon prior to submission to Cleveland Clinic Journal of Medicine. The Journal had all articles peer reviewed to ensure independence and freedom from bias.
|
Author and editor disclosures
|
From the editor:
Confessions of a goutophile: Despite its
treatability, gout remains a problem
Brian F. Mandell, MD, PhD |
The pathogenesis of gout
H. Ralph Schumacher, Jr, MD
|
Clinical manifestations of hyperuricemia and gout
Brian F. Mandell, MD, PhD |
Epidemiology of gout
Arthur L. Weaver, MD, MS |
The role of hyperuricemia and gout in kidney and cardiovascular disease
N. Lawrence Edwards, MD |
The gout diagnosis
Robin K. Dore, MD |
The practical management of gout
H. Ralph Schumacher, Jr, MD, and Lan X. Chen, MD, PhD |
|
|
|
|
|
|
|